These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||||||||
|
|
|
|
||||||||||||
|
Securities to be registered pursuant to Section 12(g) of the Act:
None
|
||||||||||||||
|
Large accelerated filer
|
o
|
|
x
|
|||||||||||
|
Non-accelerated filer
|
o
|
Smaller reporting company |
|
|||||||||||
| Emerging growth company |
|
|||||||||||||
| Page | |||||
| Part I. Financial Information | |||||
| Part II. Other Information | |||||
| 2024 Form 10-K | RYAM Annual Report on Form 10-K for the year ended December 31, 2024 | ||||
| 2029 Term Loan | $700 million original aggregate principal amount of variable rate term loan entered into October 2024, maturing October 2029 | ||||
|
ABL Credit Facility
|
$175 million 5-year senior secured asset-based revolving credit facility, as amended, maturing November 2029
|
||||
| AETR | Annual effective tax rate | ||||
| AGE | Altamaha Green Energy LLC | ||||
| ASC | Accounting Standards Codification | ||||
| ASU | Accounting Standards Update | ||||
|
AOCI
|
Accumulated other comprehensive income (loss)
|
||||
| BioNova | RYAM BioNova S.A.S., a French simplified joint-stock company and a RYAM subsidiary in which SWEN holds a redeemable noncontrolling interest | ||||
| BioNova Term Loan | €37 million aggregate principal amount of variable rate term loans entered into November 2024, maturing November 2031 and November 2032 | ||||
| CAD | Canadian dollar | ||||
| CEWS |
Canada Emergency Wage Subsidy
|
||||
| DTA | Deferred tax asset | ||||
| EBITDA | Earnings before interest, taxes, depreciation and amortization | ||||
| ERP | Enterprise Resource Planning | ||||
| Exchange Act |
Securities Exchange Act of 1934, as amended
|
||||
| FASB | Financial Accounting Standards Board | ||||
| Financial Statements | Unaudited condensed consolidated financial statements included in Part I Item 1 of this Quarterly Report on Form 10-Q | ||||
| GAAP | United States generally accepted accounting principles | ||||
| Georgia EPD | Georgia Environmental Protection Division | ||||
|
LTF
|
LignoTech Florida LLC
|
||||
| MT | Metric ton | ||||
| OPEB | Other post-employment benefits | ||||
| RCRA | Resource Conservation and Recovery Act | ||||
| ROU |
Right-of-use
|
||||
| RYAM, the Company, our, we, us | Rayonier Advanced Materials Inc. and its consolidated subsidiaries | ||||
| SEC | United States Securities and Exchange Commission | ||||
| SG&A | Selling, general and administrative expense | ||||
| SOFR |
Secured Overnight Financing Rate
|
||||
| SWEN | SWEN Impact Fund for Transition 3 | ||||
| TSR |
Total shareholder return
|
||||
|
U.S.
|
United States of America
|
||||
| USMCA | United States-Mexico-Canada Agreement | ||||
| Washington DOE | Washington Department of Ecology | ||||
| Washington MTCA |
Washington Model Toxics Control Act
|
||||
| Three Months Ended | |||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||||||||
| Net sales | $ |
|
$ |
|
|||||||||||||||||||
| Cost of sales |
(
|
(
|
|||||||||||||||||||||
| Gross margin |
|
|
|||||||||||||||||||||
| Selling, general and administrative expense |
(
|
(
|
|||||||||||||||||||||
| Foreign exchange gain (loss) |
(
|
|
|||||||||||||||||||||
| Indefinite suspension charges (Note 2) |
(
|
|
|||||||||||||||||||||
| Environmental remediation expense |
(
|
(
|
|||||||||||||||||||||
| Other operating expense, net |
(
|
(
|
|||||||||||||||||||||
| Operating income (loss) |
(
|
|
|||||||||||||||||||||
| Interest expense |
(
|
(
|
|||||||||||||||||||||
|
Components of pension and OPEB, excluding service costs (Note 14)
|
|
|
|||||||||||||||||||||
| Other income, net |
|
|
|||||||||||||||||||||
| Loss before income tax |
(
|
(
|
|||||||||||||||||||||
|
Income tax benefit (Note 15)
|
|
|
|||||||||||||||||||||
| Equity in loss of equity method investment |
(
|
(
|
|||||||||||||||||||||
| Net loss |
(
|
(
|
|||||||||||||||||||||
|
Net income attributable to redeemable noncontrolling interest (Note 10)
|
|
|
|||||||||||||||||||||
| Net loss attributable to RYAM | $ |
(
|
$ |
(
|
|||||||||||||||||||
|
Basic and Diluted earnings per common share (Note 12)
|
|||||||||||||||||||||||
| Net loss per common share | $ |
(
|
$ |
(
|
|||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||||||||
| Net loss | $ |
(
|
$ |
(
|
|||||||||||||||||||
|
Other comprehensive income (loss), net of tax (Note 11):
|
|||||||||||||||||||||||
| Foreign currency translation adjustment |
|
(
|
|||||||||||||||||||||
| Unrealized gain on derivative instruments |
|
|
|||||||||||||||||||||
| Net loss on employee benefit plans |
(
|
(
|
|||||||||||||||||||||
| Total other comprehensive income (loss) |
|
(
|
|||||||||||||||||||||
| Comprehensive loss |
(
|
(
|
|||||||||||||||||||||
| Comprehensive income attributable to redeemable noncontrolling interest |
|
|
|||||||||||||||||||||
| Comprehensive loss attributable to RYAM | $ |
(
|
$ |
(
|
|||||||||||||||||||
| March 29, 2025 | December 31, 2024 | ||||||||||
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | $ |
|
$ |
|
|||||||
|
Accounts receivable, net (Note 3)
|
|
|
|||||||||
|
Inventory (Note 4)
|
|
|
|||||||||
| Income tax receivable |
|
|
|||||||||
| Prepaid and other current assets |
|
|
|||||||||
| Total current assets |
|
|
|||||||||
|
Property, plant and equipment
(net of accumulated depreciation of $
|
|
|
|||||||||
| Deferred tax assets |
|
|
|||||||||
| Intangible assets, net |
|
|
|||||||||
| Other assets |
|
|
|||||||||
| Total assets | $ |
|
$ |
|
|||||||
| Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable | $ |
|
$ |
|
|||||||
|
Accrued and other current liabilities (Note 6)
|
|
|
|||||||||
|
Debt due within one year (Note 7)
|
|
|
|||||||||
|
Current environmental liabilities (Note 8)
|
|
|
|||||||||
| Total current liabilities |
|
|
|||||||||
|
Long-term debt (Note 7)
|
|
|
|||||||||
|
Non-current environmental liabilities (Note 8)
|
|
|
|||||||||
|
Pension and other postretirement benefits (Note 14)
|
|
|
|||||||||
| Deferred tax liabilities |
|
|
|||||||||
| Other liabilities |
|
|
|||||||||
|
Commitments and contingencies (Note 17)
|
|
|
|||||||||
|
Redeemable noncontrolling interest (Note 10)
|
|
|
|||||||||
| Stockholders’ Equity | |||||||||||
|
Common stock:
|
|
|
|||||||||
| Additional paid-in capital |
|
|
|||||||||
| Retained earnings |
|
|
|||||||||
|
Accumulated other comprehensive loss (Note 11)
|
(
|
(
|
|||||||||
| Total stockholders’ equity |
|
|
|||||||||
| Total liabilities, redeemable noncontrolling interest and stockholders’ equity | $ |
|
$ |
|
|||||||
| Common Stock | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total Stockholders’ Equity | |||||||||||||||||||||||||||||||
| Shares | Par Value | ||||||||||||||||||||||||||||||||||
|
Three months ended March 29, 2025
|
|||||||||||||||||||||||||||||||||||
|
Balance at December 31, 2024
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
|
|||||||||||||||||||||||||
| Net loss attributable to RYAM | — | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | — | — | — | — |
|
|
|||||||||||||||||||||||||||||
| Issuance of common stock under incentive stock plans |
|
|
(
|
— | — |
|
|||||||||||||||||||||||||||||
| Stock-based compensation | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
|
Repurchase of common stock
(a)
|
(
|
(
|
(
|
— | — |
(
|
|||||||||||||||||||||||||||||
| Redeemable noncontrolling interest adjustment to redemption value | — | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
|
Balance at March 29, 2025
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||||||||||
|
Three months ended March 30, 2024
|
|||||||||||||||||||||||||||||||||||
|
Balance at December 31, 2023
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||||||||||
| Net loss attributable to RYAM | — | — | — |
(
|
— |
(
|
|||||||||||||||||||||||||||||
| Other comprehensive loss, net of tax | — | — | — | — |
(
|
(
|
|||||||||||||||||||||||||||||
| Issuance of common stock under incentive stock plans |
|
|
(
|
— | — |
|
|||||||||||||||||||||||||||||
| Stock-based compensation | — | — |
|
— | — |
|
|||||||||||||||||||||||||||||
|
Repurchase of common stock
(a)
|
(
|
(
|
(
|
— | — |
(
|
|||||||||||||||||||||||||||||
|
Balance at March 30, 2024
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||||||||||
| Three Months Ended | |||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||
| Operating activities | |||||||||||
| Net loss | $ |
(
|
$ |
(
|
|||||||
| Adjustments to reconcile net loss to cash provided by operating activities: | |||||||||||
| Depreciation and amortization |
|
|
|||||||||
| Stock-based compensation expense |
|
|
|||||||||
| Deferred income tax benefit |
(
|
|
|||||||||
| Increase in environmental liabilities |
|
|
|||||||||
| Change in fair value of put option liability |
|
|
|||||||||
| Net periodic benefit cost of pension and other postretirement plans |
|
|
|||||||||
| Unrealized (gain) loss on foreign currency |
|
(
|
|||||||||
| Other |
|
|
|||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable |
|
|
|||||||||
| Inventory |
(
|
(
|
|||||||||
| Accounts payable |
|
(
|
|||||||||
| Accrued and other current liabilities |
(
|
(
|
|||||||||
| Other |
(
|
|
|||||||||
| Contributions to pension and other postretirement plans |
(
|
(
|
|||||||||
| Cash provided by operating activities |
|
|
|||||||||
| Investing activities | |||||||||||
| Capital expenditures, net of proceeds |
(
|
(
|
|||||||||
| Cash used in investing activities |
(
|
(
|
|||||||||
| Financing activities | |||||||||||
| Borrowings of long-term debt |
|
|
|||||||||
| Repayments of long-term debt |
(
|
(
|
|||||||||
| Short-term financing, net |
|
(
|
|||||||||
| Debt issuance costs |
|
(
|
|||||||||
| Repurchase of common stock |
(
|
(
|
|||||||||
| Cash provided by (used in) financing activities |
(
|
|
|||||||||
| Net increase (decrease) in cash and cash equivalents |
|
(
|
|||||||||
| Net effect of foreign exchange on cash and cash equivalents |
|
(
|
|||||||||
| Balance, beginning of period |
|
|
|||||||||
| Balance, end of period | $ |
|
$ |
|
|||||||
| Supplemental cash flow information: | |||||||||||
| Interest paid | $ |
(
|
$ |
(
|
|||||||
| Income taxes refunded, net |
|
|
|||||||||
| Capital assets purchased on account |
|
|
|||||||||
| Mothballing Costs | Severance and Other Employee Costs | Total | |||||||||||||||||||||
|
Balance at December 31, 2024
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||
| Charges incurred |
|
(
|
|
||||||||||||||||||||
| Payments |
(
|
(
|
(
|
||||||||||||||||||||
|
Balance at March 29, 2025
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||
| March 29, 2025 | December 31, 2024 | ||||||||||
| Accounts receivable, trade | $ |
|
$ |
|
|||||||
|
Accounts receivable, other
(a)
|
|
|
|||||||||
| Allowance for credit loss |
(
|
(
|
|||||||||
| Accounts receivable, net | $ |
|
$ |
|
|||||||
| March 29, 2025 | December 31, 2024 | ||||||||||
| Finished goods | $ |
|
$ |
|
|||||||
| Work-in-progress |
|
|
|||||||||
| Raw materials |
|
|
|||||||||
| Manufacturing and maintenance supplies |
|
|
|||||||||
| Inventory | $ |
|
$ |
|
|||||||
| Three Months Ended | |||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||||||||
| Operating lease cost | $ |
|
$ |
|
|||||||||||||||||||
| Finance lease cost | |||||||||||||||||||||||
| Amortization of ROU assets |
|
|
|||||||||||||||||||||
| Interest |
|
|
|||||||||||||||||||||
| Total lease cost | $ |
|
$ |
|
|||||||||||||||||||
| Balance Sheet Location | March 29, 2025 | December 31, 2024 | |||||||||||||||
| Operating leases | |||||||||||||||||
| ROU assets | Other assets | $ |
|
$ |
|
||||||||||||
| Lease liabilities, current | Accrued and other current liabilities |
|
|
||||||||||||||
| Lease liabilities, non-current | Other liabilities |
|
|
||||||||||||||
| Finance leases | |||||||||||||||||
| ROU assets | Property, plant and equipment, net | $ |
|
$ |
|
||||||||||||
| Lease liabilities | Long-term debt |
|
|
||||||||||||||
| Three Months Ended | |||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||
| Operating cash flows - cash paid for amounts included in the measurement of operating lease liabilities | $ |
|
$ |
|
|||||||
| Operating lease ROU assets obtained in exchange for lease liabilities |
|
|
|||||||||
| March 29, 2025 | December 31, 2024 | ||||||||||||||||||||||
| Operating leases | |||||||||||||||||||||||
| Weighted average remaining lease term (in years) |
|
|
|||||||||||||||||||||
| Weighted average discount rate |
|
% |
|
% | |||||||||||||||||||
| Finance leases | |||||||||||||||||||||||
| Weighted average remaining lease term (in years) |
|
|
|||||||||||||||||||||
| Weighted average discount rate |
|
% |
|
% | |||||||||||||||||||
| Remainder of 2025 | $ |
|
|||
| 2026 |
|
||||
| 2027 |
|
||||
| 2028 |
|
||||
| 2029 |
|
||||
| Thereafter |
|
||||
| Total minimum lease payments |
|
||||
| Less: imputed interest |
(
|
||||
| Present value of future minimum lease payments | $ |
|
|||
| March 29, 2025 | December 31, 2024 | ||||||||||
| Accrued customer incentives | $ |
|
$ |
|
|||||||
| Accrued payroll and benefits |
|
|
|||||||||
| Accrued interest |
|
|
|||||||||
| Accrued income taxes |
|
|
|||||||||
| Accrued property and other taxes |
|
|
|||||||||
|
Deferred revenue
(a)
|
|
|
|||||||||
|
Other current liabilities
(b)
|
|
|
|||||||||
| Accrued and other current liabilities | $ |
|
$ |
|
|||||||
| March 29, 2025 | December 31, 2024 | ||||||||||
|
ABL Credit Facility due November 2029: $
|
$ |
|
$ |
|
|||||||
|
2029 Term Loan due October 2029: bearing interest of
|
|
|
|||||||||
|
|
|
|
|||||||||
|
BioNova debt
(a)
|
|
|
|||||||||
|
Other loans
(b)
|
|
|
|||||||||
| Short-term factoring facility |
|
|
|||||||||
| Finance lease obligations |
|
|
|||||||||
| Total principal payments due |
|
|
|||||||||
| Less: unamortized premium, discount and issuance costs |
(
|
(
|
|||||||||
| Total debt |
|
|
|||||||||
| Less: debt due within one year |
(
|
(
|
|||||||||
| Long-term debt | $ |
|
$ |
|
|||||||
| Remainder of 2025 | $ |
|
|||
| 2026 |
|
||||
| 2027 |
|
||||
| 2028 |
|
||||
| 2029 |
|
||||
| Thereafter |
|
||||
| Total debt principal payments | $ |
|
|||
|
Balance at December 31, 2024
|
$ |
|
|||
| Increase in liabilities |
|
||||
| Payments |
(
|
||||
| Foreign currency adjustments |
(
|
||||
|
Balance at March 29, 2025
|
|
||||
| Less: current portion |
(
|
||||
| Non-current environmental liabilities | $ |
|
|||
| Financial Statement Line Item | |||||||||||
|
Balance at December 31, 2024
|
Other liabilities | $ |
|
||||||||
| Fair value measurement adjustment | Other income, net |
|
|||||||||
| Foreign currency translation adjustment | Foreign currency translation adjustment |
|
|||||||||
|
Balance at March 29, 2025
|
Other liabilities | $ |
|
||||||||
| March 29, 2025 | December 31, 2024 | ||||||||||
|
Free cash flow to equity volatility
(a)
|
|
% |
|
% | |||||||
| Risk-free interest rate | Term structure of U.S. Treasury and Euro Government Bond securities | Term structure of U.S. Treasury and Euro Government Bond securities | |||||||||
| Weighted average cost of capital |
|
% |
|
% | |||||||
| March 29, 2025 | December 31, 2024 | ||||||||||
|
Carrying amount of fixed rate debt
(a)
|
$ |
|
$ |
|
|||||||
| Fair value of fixed rate debt | $ |
|
$ |
|
|||||||
| Redeemable Noncontrolling Interest | |||||
|
Balance at December 31, 2024
|
$ |
|
|||
| Adjustment to redemption value |
|
||||
| Net income attributable to redeemable noncontrolling interest |
|
||||
| Comprehensive income adjustments: | |||||
| Foreign currency translation adjustment on redemption value |
|
||||
|
Balance at March 29, 2025
|
$ |
|
|||
| Three Months Ended | |||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||
| Unrecognized components of employee benefit plans, net of tax | |||||||||||
| Balance, beginning of period | $ |
(
|
$ |
(
|
|||||||
|
Reclassifications to earnings
(a)
|
|||||||||||
| Amortization of gain |
(
|
(
|
|||||||||
| Amortization of prior service cost |
|
|
|||||||||
| Income tax on reclassifications |
|
|
|||||||||
| Net comprehensive loss on employee benefit plans, net of tax |
(
|
(
|
|||||||||
| Balance, end of period |
(
|
(
|
|||||||||
| Unrealized loss on derivative instruments, net of tax | |||||||||||
| Balance, beginning of period |
(
|
(
|
|||||||||
|
Reclassifications to earnings - foreign currency exchange contracts
(b)
|
|
|
|||||||||
| Income tax on reclassifications |
(
|
(
|
|||||||||
| Net comprehensive gain on derivative instruments, net of tax |
|
|
|||||||||
| Balance, end of period |
(
|
(
|
|||||||||
| Foreign currency translation | |||||||||||
| Balance, beginning of period |
(
|
(
|
|||||||||
|
Foreign currency translation adjustment, net of tax
(c)
|
|
(
|
|||||||||
| Balance, end of period |
(
|
(
|
|||||||||
| Accumulated other comprehensive loss, end of period | $ |
(
|
$ |
(
|
|||||||
| Three Months Ended | |||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||||||||
| Net loss | $ |
(
|
$ |
(
|
|||||||||||||||||||
| Net income attributable to redeemable noncontrolling interest |
|
|
|||||||||||||||||||||
| Net loss attributable to RYAM |
(
|
(
|
|||||||||||||||||||||
| Less: Redeemable noncontrolling interest adjustment to redemption value |
(
|
|
|||||||||||||||||||||
| Net loss attributable to RYAM common stockholders | $ |
(
|
$ |
(
|
|||||||||||||||||||
| Weighted average shares used for determining earnings per share of common stock - basic and diluted |
|
|
|||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||||||||
| Performance and restricted stock |
|
|
|||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||||||||
|
Stock plan compensation expense
|
$ |
|
$ |
|
|||||||||||||||||||
| Restricted Stock Units | Performance-Based Stock Units | ||||||||||||||||||||||||||||||||||
| Awards | Weighted Average Grant Date Fair Value | Awards | Weighted Average Grant Date Fair Value | ||||||||||||||||||||||||||||||||
|
Outstanding at December 31, 2024
|
|
$ |
|
|
$ |
|
|||||||||||||||||||||||||||||
| Granted |
|
$ |
|
|
$ |
|
|||||||||||||||||||||||||||||
| Forfeited |
(
|
$ |
|
(
|
$ |
|
|||||||||||||||||||||||||||||
| Exercised or settled |
(
|
$ |
|
(
|
$ |
|
|||||||||||||||||||||||||||||
|
Outstanding at March 29, 2025
|
|
$ |
|
|
$ |
|
|||||||||||||||||||||||||||||
| Pension | Postretirement | ||||||||||||||||||||||
| Three Months Ended | Three Months Ended | ||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | March 29, 2025 | March 30, 2024 | ||||||||||||||||||||
| Service cost | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Interest cost |
|
|
|
|
|||||||||||||||||||
| Expected return on plan assets |
(
|
(
|
|
|
|||||||||||||||||||
| Amortization of prior service cost (credit) |
|
|
(
|
(
|
|||||||||||||||||||
| Amortization of gain |
|
(
|
(
|
(
|
|||||||||||||||||||
| Net periodic benefit cost | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||||||||
|
Loss before income tax
|
$ |
(
|
$ |
(
|
|||||||||||||||||||
| Effective tax rate |
|
% |
|
% | |||||||||||||||||||
|
Three Months Ended March 29, 2025
|
|||||||||||||||||||||||||||||||||||||||||
| Cellulose Specialties | Cellulose Commodities | Biomaterials | Paperboard | High-Yield Pulp |
Corporate
(a)
and Eliminations
|
Total | |||||||||||||||||||||||||||||||||||
| Net sales | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||||||||||||||||||||||
| Key input costs (wood, chemicals, energy) |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Freight |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Depreciation and amortization |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
Fixed and other general costs
(b)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Total cost of sales |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Selling, general and administrative expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Indefinite suspension charges |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
Other operating expense, net
(c)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ |
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||
| Total depreciation and amortization | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
|
Three Months Ended March 30, 2024
|
|||||||||||||||||||||||||||||||||||||||||
| Cellulose Specialties | Cellulose Commodities | Biomaterials | Paperboard | High-Yield Pulp |
Corporate
(a)
and Eliminations
|
Total | |||||||||||||||||||||||||||||||||||
| Net sales | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||||||||||||||||||||||
| Key input costs (wood, chemicals, energy) |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Freight |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Depreciation and amortization |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
Fixed and other general costs
(b)
|
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Total cost of sales |
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||
| Selling, general and administrative expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
Other operating (income) expense, net
(c)
|
|
|
(
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
| Operating income (loss) | $ |
|
$ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
| Total depreciation and amortization | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| March 29, 2025 | December 31, 2024 | ||||||||||||||||
| Cellulose Specialties | $ |
|
$ |
|
|||||||||||||
| Cellulose Commodities |
|
|
|||||||||||||||
| Biomaterials |
|
|
|||||||||||||||
| Paperboard |
|
|
|||||||||||||||
| High-Yield Pulp |
|
|
|||||||||||||||
|
Shared/Corporate
(a)
|
|
|
|||||||||||||||
| Total assets | $ |
|
$ |
|
|||||||||||||
| Three Months Ended | |||||||||||||||||
| March 29, 2025 | March 30, 2024 | ||||||||||||||||
| Cellulose Specialties | $ |
|
$ |
|
|||||||||||||
| Cellulose Commodities |
|
|
|||||||||||||||
| Biomaterials |
|
|
|||||||||||||||
| Paperboard |
|
|
|||||||||||||||
| High-Yield Pulp |
|
|
|||||||||||||||
|
Shared/Corporate
(a)
|
|
|
|||||||||||||||
|
Total capital additions
(b)
|
$ |
|
$ |
|
|||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions, except percentages) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Net sales | $ | 356 | $ | 388 | |||||||||||||||||||
| Cost of sales | (332) | (351) | |||||||||||||||||||||
| Gross margin | 24 | 37 | |||||||||||||||||||||
| Selling, general and administrative expense | (23) | (21) | |||||||||||||||||||||
| Foreign exchange gain (loss) | (1) | 3 | |||||||||||||||||||||
| Indefinite suspension charges | — | — | |||||||||||||||||||||
| Other operating (expense), net | (15) | (2) | |||||||||||||||||||||
| Operating income (loss) | (15) | 17 | |||||||||||||||||||||
| Interest expense | (24) | (21) | |||||||||||||||||||||
| Components of pension and OPEB, excluding service costs | 1 | 1 | |||||||||||||||||||||
| Other income, net | 1 | 1 | |||||||||||||||||||||
| Loss before income tax | (37) | (2) | |||||||||||||||||||||
| Income tax benefit | 5 | — | |||||||||||||||||||||
| Equity in loss of equity method investment | — | — | |||||||||||||||||||||
| Net loss | (32) | (2) | |||||||||||||||||||||
| Net income attributable to redeemable noncontrolling interest | — | — | |||||||||||||||||||||
| Net loss attributable to RYAM | $ | (32) | $ | (2) | |||||||||||||||||||
| Gross margin % | 6.7 | % | 9.5 | % | |||||||||||||||||||
| Operating margin % | (4.2) | % | 4.4 | % | |||||||||||||||||||
| Effective tax rate | 15.0 | % | 29.7 | % | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Cellulose Specialties | $ | 201 | $ | 206 | |||||||||||||||||||
| Cellulose Commodities | 75 | 94 | |||||||||||||||||||||
| Biomaterials | 7 | 7 | |||||||||||||||||||||
| Paperboard | 49 | 53 | |||||||||||||||||||||
| High-Yield Pulp | 31 | 34 | |||||||||||||||||||||
| Eliminations | (7) | (6) | |||||||||||||||||||||
| Net sales | $ | 356 | $ | 388 | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Cellulose Specialties | $ | 31 | $ | 38 | |||||||||||||||||||
| Cellulose Commodities | (13) | (19) | |||||||||||||||||||||
| Biomaterials | 2 | 2 | |||||||||||||||||||||
| Paperboard | (2) | 8 | |||||||||||||||||||||
| High-Yield Pulp | (7) | (1) | |||||||||||||||||||||
| Corporate | (26) | (11) | |||||||||||||||||||||
| Operating income (loss) | $ | (15) | $ | 17 | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions, unless otherwise stated) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Net sales | $ | 201 | $ | 206 | |||||||||||||||||||
| Operating income | $ | 31 | $ | 38 | |||||||||||||||||||
| Average sales prices ($ per MT) | $ | 1,750 | $ | 1,724 | |||||||||||||||||||
| Sales volumes (thousands of MTs) | 111 | 113 | |||||||||||||||||||||
|
Three Months Ended March 30, 2024
|
Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||
| (in millions) | Price | Volume/Mix/Other | |||||||||||||||||||||
| Net sales | $ | 206 | $ | 3 | $ | (8) | $ | 201 | |||||||||||||||
|
Three Months Ended March 30, 2024
|
Gross Margin Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||||||||||||||
|
(in millions, except percentages)
|
Sales Price |
Sales Volume/Mix/Other
(a)
|
Cost | SG&A and other | |||||||||||||||||||||||||||||||
| Operating income | $ | 38 | $ | 3 | $ | (6) | $ | (3) | $ | (1) | $ | 31 | |||||||||||||||||||||||
| Operating margin % | 18.4 | % | 1.2 | % | (2.2) | % | (1.5) | % | (0.5) | % | 15.4 | % | |||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions, unless otherwise stated) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Net sales | $ | 75 | $ | 94 | |||||||||||||||||||
| Operating loss | $ | (13) | $ | (19) | |||||||||||||||||||
| Average sales prices ($ per MT) | $ | 863 | $ | 842 | |||||||||||||||||||
| Sales volumes (thousands of MTs) | 84 | 106 | |||||||||||||||||||||
|
Three Months Ended March 30, 2024
|
Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||
| (in millions) | Price | Volume/Mix/Other | |||||||||||||||||||||
| Net sales | $ | 94 | $ | — | $ | (19) | $ | 75 | |||||||||||||||
|
Three Months Ended March 30, 2024
|
Gross Margin Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||||||||||||||
|
(in millions, except percentages)
|
Sales Price |
Sales Volume/Mix/Other
(a)
|
Cost | SG&A and other | |||||||||||||||||||||||||||||||
| Operating loss | $ | (19) | $ | — | $ | (11) | $ | 18 | $ | (1) | $ | (13) | |||||||||||||||||||||||
| Operating margin % | (20.2) | % | — | % | (19.8) | % | 24.0 | % | (1.3) | % | (17.3) | % | |||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Net sales | $ | 7 | $ | 7 | |||||||||||||||||||
| Operating income | $ | 2 | $ | 2 | |||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions, unless otherwise stated) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Net sales | $ | 49 | $ | 53 | |||||||||||||||||||
| Operating income (loss) | $ | (2) | $ | 8 | |||||||||||||||||||
| Average sales prices ($ per MT) | $ | 1,321 | $ | 1,382 | |||||||||||||||||||
| Sales volumes (thousands of MTs) | 37 | 38 | |||||||||||||||||||||
|
Three Months Ended March 30, 2024
|
Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||
| (in millions) | Price | Volume/Mix | |||||||||||||||||||||
| Net sales | $ | 53 | $ | (2) | $ | (2) | $ | 49 | |||||||||||||||
|
Three Months Ended March 30, 2024
|
Gross Margin Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||||||||||||||
|
(in millions, except percentages)
|
Sales Price |
Sales Volume/Mix
(a)
|
Cost | SG&A and other | |||||||||||||||||||||||||||||||
| Operating income (loss) | $ | 8 | $ | (2) | $ | (1) | $ | (6) | $ | (1) | $ | (2) | |||||||||||||||||||||||
| Operating margin % | 15.1 | % | (3.3) | % | (1.6) | % | (12.2) | % | (2.1) | % | (4.1) | % | |||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
| (in millions, unless otherwise stated) | March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Net sales | $ | 31 | $ | 34 | |||||||||||||||||||
| Operating loss | $ | (7) | $ | (1) | |||||||||||||||||||
|
Average sales prices ($ per MT)
(a)
|
$ | 518 | $ | 559 | |||||||||||||||||||
|
Sales volumes (thousands of MTs)
(a)
|
48 | 50 | |||||||||||||||||||||
|
Three Months Ended March 30, 2024
|
Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||
|
(in millions)
|
Price | Volume/Mix | |||||||||||||||||||||
| Net sales | $ | 34 | $ | (2) | $ | (1) | $ | 31 | |||||||||||||||
|
Three Months Ended March 30, 2024
|
Gross Margin Changes Attributable to: |
Three Months Ended March 29, 2025
|
|||||||||||||||||||||||||||||||||
|
(in millions, except percentages)
|
Sales Price |
Sales Volume/Mix
(a)
|
Cost | SG&A and other | |||||||||||||||||||||||||||||||
| Operating loss | $ | (1) | $ | (2) | $ | — | $ | (4) | $ | — | $ | (7) | |||||||||||||||||||||||
| Operating margin % | (2.9) | % | (6.4) | % | (0.3) | % | (13.0) | % | — | % | (22.6) | % | |||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||
|
(in millions)
|
March 29, 2025 | March 30, 2024 | |||||||||||||||||||||
| Operating loss | $ | (26) | $ | (11) | |||||||||||||||||||
| (in millions, except ratios) | March 29, 2025 | December 31, 2024 | |||||||||
| Cash and cash equivalents | $ | 130 | $ | 125 | |||||||
|
Availability under the ABL Credit Facility
(a)(b)
|
$ | 131 | $ | 141 | |||||||
|
Total debt
(b)
|
$ | 736 | $ | 730 | |||||||
| Stockholders’ equity | $ | 688 | $ | 714 | |||||||
| Total capitalization (total debt plus stockholders’ equity) | $ | 1,424 | $ | 1,444 | |||||||
| Debt to capital ratio | 52 | % | 51 | % | |||||||
| Three Months Ended | |||||||||||
| (in millions) | March 29, 2025 | March 30, 2024 | |||||||||
| Cash flows provided by (used in): | |||||||||||
| Operating activities | $ | 40 | $ | 12 | |||||||
| Investing activities | (38) | (33) | |||||||||
| Financing activities | (1) | 1 | |||||||||
|
(in millions)
|
Cellulose Specialties | Cellulose Commodities | Biomaterials | Paperboard | High-Yield Pulp | Corporate | Total | ||||||||||||||||||||||||||||||||||
|
Three Months Ended March 29, 2025
|
|||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 31 | $ | (12) | $ | 1 | $ | (1) | $ | (7) | $ | (44) | $ | (32) | |||||||||||||||||||||||||||
| Net income attributable to redeemable noncontrolling interest | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Net income (loss) attributable to RYAM | 31 | (12) | 1 | (1) | (7) | (44) | (32) | ||||||||||||||||||||||||||||||||||
| Depreciation and amortization | 15 | 10 | 1 | 5 | 1 | (1) | 31 | ||||||||||||||||||||||||||||||||||
| Interest expense, net | — | — | — | — | — | 23 | 23 | ||||||||||||||||||||||||||||||||||
| Income tax expense | — | — | — | — | — | (5) | (5) | ||||||||||||||||||||||||||||||||||
| EBITDA attributable to RYAM | 46 | (2) | 2 | 4 | (6) | (27) | 17 | ||||||||||||||||||||||||||||||||||
| Indefinite suspension charges | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Adjusted EBITDA attributable to RYAM | $ | 46 | $ | (2) | $ | 2 | $ | 4 | $ | (6) | $ | (27) | $ | 17 | |||||||||||||||||||||||||||
|
Three Months Ended March 30, 2024
|
|||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 38 | $ | (19) | $ | 2 | $ | 8 | $ | (1) | $ | (30) | $ | (2) | |||||||||||||||||||||||||||
| Net income attributable to redeemable noncontrolling interest | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| Net income (loss) attributable to RYAM | 38 | (19) | 2 | 8 | (1) | (30) | (2) | ||||||||||||||||||||||||||||||||||
| Depreciation and amortization | 17 | 12 | — | 4 | 1 | — | 34 | ||||||||||||||||||||||||||||||||||
| Interest expense, net | — | — | — | — | — | 20 | 20 | ||||||||||||||||||||||||||||||||||
| Income tax benefit | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
| EBITDA and Adjusted EBITDA attributable to RYAM | $ | 55 | $ | (7) | $ | 2 | $ | 12 | $ | — | $ | (10) | $ | 52 | |||||||||||||||||||||||||||
| Three Months Ended | |||||||||||
| (in millions) | March 29, 2025 | March 30, 2024 | |||||||||
| Cash provided by operating activities | $ | 40 | $ | 12 | |||||||
|
Capital expenditures, net
(a)
|
(30) | (28) | |||||||||
| Adjusted free cash flow | $ | 10 | $ | (16) | |||||||
|
Total Number of Shares Purchased
(a)
|
Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |
Dollar Value of Shares That May Yet be Purchased Under the Plans or Programs
(b)
|
||||||||||||||||||||
| January 1 to February 1 | — | $ | — | — | $ | 60,294,000 | |||||||||||||||||
| February 2 to March 1 | 374,211 | $ | 7.55 | — | $ | 60,294,000 | |||||||||||||||||
| March 2 to March 29 | 1,215 | $ | 5.33 | — | $ | 60,294,000 | |||||||||||||||||
| Total | 375,426 | — | |||||||||||||||||||||
| Exhibit No. | Description | Location | ||||||||||||
| Amended and Restated Certificate of Incorporation of Rayonier Advanced Materials Inc., as amended | Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Form 10-K filed on March 6, 2025 | |||||||||||||
| Certificate of Designations of 8.00% Series A Mandatory Convertible Preferred Stock of Rayonier Advanced Materials Inc., filed with the Secretary of State of the State of Delaware and effective August 10, 2016 | Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on August 10, 2016 | |||||||||||||
| Certificate of Designations of Series A Junior Participating Preferred Stock | Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on March 21, 2022 | |||||||||||||
| Amended and Restated Bylaws of Rayonier Advanced Materials Inc., effective October 19, 2022 | Incorporated herein by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on October 19, 2022 | |||||||||||||
|
Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a)/15d-14(a) and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
Filed herewith
|
|||||||||||||
|
Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a)/15d-14(a) and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
Filed herewith
|
|||||||||||||
|
Certification of Periodic Financial Reports Under Section 906 of the Sarbanes-Oxley Act of 2002
|
Furnished herewith
|
|||||||||||||
| 101 | Interactive data files (formatted in Inline XBRL) pursuant to Rule 405 of Regulation S-T |
Filed herewith
|
||||||||||||
| 104 | Cover page interactive data file (formatted in Inline XBRL and contained in Exhibit 101) pursuant to Rule 406 of Regulation S-T | Filed herewith | ||||||||||||
| Rayonier Advanced Materials Inc. | ||||||||
| By: | /s/ MARCUS J. MOELTNER | |||||||
|
Marcus J. Moeltner
Chief Financial Officer and Senior Vice President, Finance
(Principal Financial Officer)
|
||||||||
|
Date: May 7, 2025
|
||||||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|